Astellas Pharma buys Ocata Therapeutics for $8.50 per share in cash

• Astellas Pharma (OTCPK:ALPMF)(OTCPK:ALPMY) acquires Ocata Therapeutics (NASDAQ:OCAT) for $8.50 per share in cash or ~$379M. The tender offer will commence no late than November 25 and will not extend beyond May 9, 2016. The transaction will enable Astellas to establish a presence in ophthalmology and a leading position in cell therapy.
• The deal is not expected to impact Astellas' fiscal year (ended March 31) financials to a significant degree.
• OCAT closed yesterday at $4.46.